 | | Vol. 15.45 – 17 November, 2021 |
| |
|
|
| Scientists utilized patient-derived induced pluripotent stem cells to generate 3D cerebral organoids to model neuropathology of schizophrenia during its early-arising neurodevelopmental period.
[Molecular Psychiatry] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Tamoxifen-inducible and microglia-specific depletion of polyglutamine binding protein 1 (PQBP1) in primary culture in vitro and mouse brain in vivo showed that PQBP1 was essential for sensing-tau to induce nuclear translocation of nuclear factor κB.
[Nature Communications] |
|
|
|
| Whether sensory neuronal activity is important for tumor progression remains unknown. Researchers suggested that sensory innervations regulate melanoma progression, indicating that manipulation of sensory neurons’ activity may provide a valuable tool to improve melanoma patients’ outcomes.
[Acta Neuropathologica Communications] |
|
|
|
| Scientists developed a highly standardized, reproducible and fast murine brain organoid model starting from embryonic neural stem cells.
[iScience] |
|
|
|
| Investigators used a barcode labeling approach of glioma-initiating cells to generate clonal populations over a number of passages, in combination with phenotyping using the established stem cell markers CD133, CD15, CD44, and A2B5.
[Laboratory Investigation] |
|
|
|
| The receptor tyrosine kinase AXL has been identified as an entry receptor for Zika virus (ZIKV) in a cell type-specific manner. AXL was frequently overexpressed in glioblastoma (GBM) patients. The authors demonstrated that ZIKV entry into GBM cells in vitro was mediated by the AXL receptor.
[Molecular Therapy-Oncolytics] |
|
|
|
| Investigators concluded that both Beclin1 and Puma played essential roles in the neuronal death caused by the induction of aberrant autophagy in Alzheimer’s disease and that targeting their interaction could be vital to understand the crosstalk of autophagy and apoptosis.
[Cell Death Discovery] |
|
|
|
| Accumulating evidence revealed that long noncoding RNAs have been participating in cancer malignant progression, including glioblastoma multiforme (GBM). Scientists illuminated the definite mechanism of HNF1A-AS1 in promoting GBM malignancy.
[Cell Death Discovery] |
|
|
|
| Differentiation platforms were established to model neural induction from stem cells, and investigators characterized these differentiated cell types by 10x single cell RNA sequencing.
[Scientific Reports] |
|
|
|
| Researchers provided a proof-of-concept that human embryonic stem cell-derived neurons could integrate and modulate the activity of a human host neuronal network.
[Scientific Reports] |
|
 |
|
|
|
| Scientists review recent progress on uncovering the cellular and molecular principles of human brain organogenesis in vivo as well as using organoids and assembloids in vitro to model features of human evolution and disease.
[Cell] |
|
|
|
| The authors review evidence in favor of stem cell–derived neuronal-based screening approaches for the identification of analgesic targets and compounds for treating diverse forms of acute and chronic pain.
[Science Translational Medicine] |
|
|
|
| Investigators review current knowledge about IDH wild-type enzymes and their putative role in mechanisms driving tumor progression, and present the diverse metabolic function of IDH enzymes and their roles in glioblastoma initiation, progression and response to treatments.
[Oncogene] |
|
|
|
|
| Denali Therapeutics, Inc. announced that its strategic partner Takeda Pharmaceutical Company Limited has exercised an option to co-develop and co-commercialize DNL593, an investigational, brain-penetrant progranulin replacement therapy for the potential treatment of frontotemporal dementia-granulin.
[Denali Therapeutics, Inc.] |
|
|
|
| Horizon Therapeutics plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for UPLIZNA® as a monotherapy for the treatment of adult patients with NMOSD.
[Horizon Therapeutics plc] |
|
|
|
|
| December 6 – 8, 2021
Melbourne, Victoria, Australia |
|
|
|
|
|
| | Rutgers University – New Brunswick, New Jersey, United States |
|
|
|
| | SickKids Research Institute – Toronto, Ontario, Canada |
|
|
|
| | The University of Hong Kong – Hong Kong, China |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | University of Calgary – Calgary, Alberta, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
